The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; Sanofi; SERVIER; Takeda; TG Therapeutics; Verastem
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Celltrion; EUSA Pharma; Gilead Sciences; Immune Design; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Portola Pharmaceuticals; Roche; Sandoz; SERVIER; Verastem
ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
 
Laurie Helen Sehn
Honoraria - Abbvie; Acerta Pharma; Amgen; Apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen-Ortho; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; morphosys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG Therapeutics; Verastem
Consulting or Advisory Role - Abbvie; Acerta Pharma; Amgen; Amgen; apobiologix; AstraZeneca; Celgene; Debiopharm Group; Genmab; Gilead Sciences; Incyte; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; MorphoSys; Roche/Genentech; Sandoz-Novartis; Seagen; Takeda; Teva; TG Therapeutics; TG therapeutics; Verastem
Research Funding - Roche/Genentech (Inst); Teva (Inst)
 
Brad S. Kahl
Consulting or Advisory Role - Abbvie; Acerta Pharma; ADC Therapeutics; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Celgene; Genentech; Incyte; Janssen; Karyopharm Therapeutics; Kite/Gilead; MEI Pharma; Molecular Templates; MorphoSys; Pharmacyclics; Pharmacyclics; Roche; Teva
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Celgene (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Abbvie; Celgene; Genentech/Roche; Juno Therapeutics; Millennium; Seagen
 
Matthew J. Matasar
Stock and Other Ownership Interests - Merck
Honoraria - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Seagen; Takeda
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Genentech; Juno Therapeutics; Merck; Roche; Rocket Medical; Seagen; Takeda; Teva
Research Funding - Bayer; Genentech; GlaxoSmithKline; IGM Biosciences; IGM Biosciences; Immunovaccine; Janssen; Pharmacyclics; Roche; Rocket Medical; Seagen
Travel, Accommodations, Expenses - Bayer; Genentech; Roche; Seagen
 
Georg Lenz
Honoraria - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; MorphoSys; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; MorphoSys; Novartis; Roche/Genentech
Research Funding - AGIOS; Aquinox; AstraZeneca; Bayer; Gilead Sciences; Janssen-Cilag; MorphoSys; Roche/Genentech; Verastem
Expert Testimony - MorphoSys
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Janssen-Cilag; Roche/Genentech
 
Koji Izutsu
Honoraria - Abbvie; Allergan; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Fujifilm; HUYA Bioscience International; Janssen; Janssen; Kyowa Kirin; MSD; Mundipharma; Novartis; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Celgene; Kyowa Kirin; Ono Pharmaceutical
Research Funding - Chugai Pharma; Eisai
 
Weili Zhao
No Relationships to Disclose
 
Lin Tao
Employment - AstraZeneca
 
Roser Calvo
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Pier Luigi Zinzani
No Relationships to Disclose